Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer drug that has completed Phase III clinical trials to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCDA
Previous Symbol
CUSIPN/A
Phone415-429-7800
Debt
Debt-to-Equity Ratio0.11
Current Ratio12.68
Quick Ratio12.68
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees61
Outstanding Shares42,110,000
Market Cap$1.31 billion
OptionableNot Optionable
Tricida (NASDAQ:TCDA) Frequently Asked Questions
What is Tricida's stock symbol?
Tricida trades on the NASDAQ under the ticker symbol "TCDA."
How were Tricida's earnings last quarter?
Tricida Inc (NASDAQ:TCDA) posted its earnings results on Thursday, November, 8th. The company reported ($0.65) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.19. View Tricida's Earnings History.
When is Tricida's next earnings date?
What price target have analysts set for TCDA?
3 analysts have issued twelve-month price objectives for Tricida's stock. Their forecasts range from $32.00 to $50.00. On average, they anticipate Tricida's stock price to reach $38.6667 in the next year. This suggests a possible upside of 21.5% from the stock's current price. View Analyst Price Targets for Tricida.
What is the consensus analysts' recommendation for Tricida?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tricida.
Has Tricida been receiving favorable news coverage?
News stories about TCDA stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tricida earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the immediate future.
Who are some of Tricida's key competitors?
Some companies that are related to Tricida include Amneal Pharmaceuticals (AMRX), United Therapeutics (UTHR), SAGE Therapeutics (SAGE), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), Array Biopharma (ARRY), FibroGen (FGEN), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Emergent Biosolutions (EBS), Agios Pharmaceuticals (AGIO) and Evotec (EVTCY).
Who are Tricida's key executives?
Tricida's management team includes the folowing people:
- Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 47)
- Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 53)
- Dr. Wilhelm Stahl, Chief Technology Officer & Sr. VP (Age 58)
- Steffen Pietzke, VP of Fin. & Chief Accounting Officer
- Jackie Cossmon, VP of Investor Relations & Communications
When did Tricida IPO?
(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.
When does the company's lock-up period expire?
Tricida's lock-up period expires on Tuesday, December 25th. Tricida had issued 11,700,000 shares in its public offering on June 28th. The total size of the offering was $222,300,000 based on an initial share price of $19.00. After the expiration of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Who are Tricida's major shareholders?
Tricida's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (2.63%), Vanguard Group Inc. (2.59%), Vanguard Group Inc (2.59%), BlackRock Inc. (2.39%), JPMorgan Chase & Co. (1.63%) and JPMorgan Chase & Co. (1.63%). Company insiders that own Tricida stock include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Sandra I Coufal and Steffen Pietzke. View Institutional Ownership Trends for Tricida.
Which major investors are selling Tricida stock?
TCDA stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Marshall Wace North America L.P., FMR LLC and Redmile Group LLC. View Insider Buying and Selling for Tricida.
Which major investors are buying Tricida stock?
TCDA stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., BlackRock Inc., VHCP Management III LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Opaleye Management Inc. and Bank of New York Mellon Corp. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida.
How do I buy shares of Tricida?
Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tricida's stock price today?
One share of TCDA stock can currently be purchased for approximately $31.83.
How big of a company is Tricida?
Tricida has a market capitalization of $1.31 billion. Tricida employs 61 workers across the globe.
What is Tricida's official website?
How can I contact Tricida?
Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]
MarketBeat Community Rating for Tricida (NASDAQ TCDA)
MarketBeat's community ratings are surveys of what our community members think about Tricida and other stocks. Vote "Outperform" if you believe TCDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
